EPZM - Epizyme, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue10,0008,0072,560
Cost of Revenue---
Gross Profit10,0008,0072,560
Operating Expenses
Research Development109,66191,461111,209
Selling General and Administrative37,18128,37223,900
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-136,842-111,826-132,549
Income from Continuing Operations
Total Other Income/Expenses Net2,1971,614173
Earnings Before Interest and Taxes-134,645-110,212-132,376
Interest Expense---
Income Before Tax-134,645-110,212-132,376
Income Tax Expense-336--
Minority Interest---
Net Income From Continuing Ops-134,309-110,212-132,376
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-134,309-110,212-132,376
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-134,309-110,212-132,376